Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incretin hormones and the satiation signal
Jens J. Holst
International Journal of Obesity (2013) Vol. 37, Iss. 9, pp. 1161-1168
Open Access | Times Cited: 176

Showing 1-25 of 176 citing articles:

European Guidelines for Obesity Management in Adults
Volkan Yumuk, Constantine Tsigos, Martin Fried, et al.
Obesity Facts (2015) Vol. 8, Iss. 6, pp. 402-424
Open Access | Times Cited: 3103
Metabolism disrupting chemicals and metabolic disorders
Jerrold J. Heindel, Bruce Blumberg, Mathew C. Cave, et al.
Reproductive Toxicology (2016) Vol. 68, pp. 3-33
Open Access | Times Cited: 921
GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK
Daniel Beiroa, Mónica Imbernón, Rosalı́a Gallego, et al.
Diabetes (2014) Vol. 63, Iss. 10, pp. 3346-3358
Open Access | Times Cited: 507
Ghrelin, CCK, GLP-1, and PYY(3–36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB
Robert E. Steinert, Christine Feinle‐Bisset, Lori Asarian, et al.
Physiological Reviews (2016) Vol. 97, Iss. 1, pp. 411-463
Open Access | Times Cited: 488
Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention
Sin Yee Tan, Joyce Wong, Yan Sim, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2018) Vol. 13, Iss. 1, pp. 364-372
Closed Access | Times Cited: 362
Enteroendocrine cells: a review of their role in brain–gut communication
Rocco Latorre, Catia Sternini, Roberto De Giorgio, et al.
Neurogastroenterology & Motility (2015) Vol. 28, Iss. 5, pp. 620-630
Open Access | Times Cited: 313
Non‐alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches
Detlef Schuppan, Jörn M. Schattenberg
Journal of Gastroenterology and Hepatology (2013) Vol. 28, Iss. S1, pp. 68-76
Closed Access | Times Cited: 239
Probiotics: How Effective Are They in the Fight against Obesity?
Kiran Mazloom, Imran Siddiqi, Mihai Covașă
Nutrients (2019) Vol. 11, Iss. 2, pp. 258-258
Open Access | Times Cited: 170
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Daniel B. Maselli, Michael Camilleri
Advances in experimental medicine and biology (2020), pp. 171-192
Closed Access | Times Cited: 141
Regulation of Postabsorptive and Postprandial Glucose Metabolism by Insulin-Dependent and Insulin-Independent Mechanisms: An Integrative Approach
George Dimitriadis, Eirini Maratou, Aikaterini Kountouri, et al.
Nutrients (2021) Vol. 13, Iss. 1, pp. 159-159
Open Access | Times Cited: 129
Effects of Diet, Lifestyle, Chrononutrition and Alternative Dietary Interventions on Postprandial Glycemia and Insulin Resistance
Emilia Papakonstantinou, Oikonomou Christina, George‐John E. Nychas, et al.
Nutrients (2022) Vol. 14, Iss. 4, pp. 823-823
Open Access | Times Cited: 111
Fermented foods: Harnessing their potential to modulate the microbiota-gut-brain axis for mental health
Ramya Balasubramanian, Elizabeth Schneider, Eoin Gunnigle, et al.
Neuroscience & Biobehavioral Reviews (2024) Vol. 158, pp. 105562-105562
Open Access | Times Cited: 27
Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Young Min Cho, Yukihiro Fujita, Timothy J. Kieffer
Annual Review of Physiology (2013) Vol. 76, Iss. 1, pp. 535-559
Open Access | Times Cited: 162
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
Thomas F. Dejgaard, Christian S. Frandsen, Tanja Stenbæk Hansen, et al.
The Lancet Diabetes & Endocrinology (2015) Vol. 4, Iss. 3, pp. 221-232
Closed Access | Times Cited: 149
Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies
Stanley M. H. Chan, Stavros Selemidis, Steven Bozinovski, et al.
Pharmacology & Therapeutics (2019) Vol. 198, pp. 160-188
Open Access | Times Cited: 132
Weight Management in Patients with Type 1 Diabetes and Obesity
Adham Mottalib, Megan Kasetty, Jessica Mar, et al.
Current Diabetes Reports (2017) Vol. 17, Iss. 10
Open Access | Times Cited: 129
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
Christian S. Frandsen, Thomas F. Dejgaard, Sten Madsbad
The Lancet Diabetes & Endocrinology (2016) Vol. 4, Iss. 9, pp. 766-780
Closed Access | Times Cited: 90
Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
Stefan Trapp, Daniel I. Brierley
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 557-570
Open Access | Times Cited: 87
Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion
Van B. Lu, Fiona M. Gribble, Frank Reimann
Nutrients (2021) Vol. 13, Iss. 3, pp. 883-883
Open Access | Times Cited: 66
Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study
Jesse Richards, Neha Bang, Erin L. Ratliff, et al.
Obesity Pillars (2023) Vol. 7, pp. 100080-100080
Open Access | Times Cited: 36
Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions – a narrative review
Hanna Huber, Alina Schieren, Jens J. Holst, et al.
American Journal of Clinical Nutrition (2024) Vol. 119, Iss. 3, pp. 599-627
Open Access | Times Cited: 8
Specificity and sensitivity of commercially available assays for glucagon‐like peptide‐1 (GLP‐1): implications for GLP‐1 measurements in clinical studies
Monika Bąk, Nicolai J. Wewer Albrechtsen, Jens Pedersen, et al.
Diabetes Obesity and Metabolism (2014) Vol. 16, Iss. 11, pp. 1155-1164
Closed Access | Times Cited: 94
Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study
Christian S. Frandsen, Thomas F. Dejgaard, Jens J. Holst, et al.
Diabetes Care (2015) Vol. 38, Iss. 12, pp. 2250-2257
Closed Access | Times Cited: 89
Pharmacotherapy for obesity: novel agents and paradigms
Sean Manning, Andrea Pucci, Nick Finer
Therapeutic Advances in Chronic Disease (2014) Vol. 5, Iss. 3, pp. 135-148
Open Access | Times Cited: 89
User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists
Charles F. Shaefer, Pamela Kushner, Richard Aguilar
Postgraduate Medicine (2015) Vol. 127, Iss. 8, pp. 818-826
Closed Access | Times Cited: 87
Page 1 - Next Page

Scroll to top